Case Report

Coronary Vasospasm Mimicking ST-Elevation Myocardial Infarction in a Patient With ATRA-Induced Differentiation Syndrome: A case Report and Review of Literature

Khawar Maqsood\textsuperscript{a,}d, Ghazi Mirranib, Nosheen Sarwarb, James F. Burkec

Abstract

All-trans retinoic acid (ATRA) has revolutionized the treatment of acute promyelocytic leukemia (APL). Differentiation syndrome is a frequent side effect of ATRA seen in patients with APL. We describe a case of chest pain with inferior ST elevations in a patient with ATRA induced differentiation syndrome. Patient was rushed for cardiac catheterization but his pain and EKG changes resolved after nitroglycerine administration in the catheterization lab. His coronary angiogram did not show any significant lesions raising concern for coronary vasospasm as the underlying cause for pain and EKG changes. Only one case of ATRA related MI has been described in literature before.

Keywords: All-trans retinoic acid; Coronary vasospasm; Differentiation syndrome

Introduction

Coronary vasospasm has been described in association with chemotherapy such as 5-FU and capecitabine [1-4]. All-trans retinoic acid (ATRA) is used in treatment of acute promyelocytic leukemia (APL) [5]. Differentiation syndrome is an unpredictable but frequent side effect of ATRA seen in patients with APL [6]. We describe a case of coronary vasospasm mimicking inferior ST-elevation myocardial infarction (STEMI) in a patient with ATRA-induced differentiation syndrome.

Case Report

A 65-year-old Caucasian gentleman with past medical history of hypertension, ulcerative colitis and group-B streptococcal sepsis was admitted for induction chemotherapy for a new diagnosis of acute promyelocytic leukemia (APL). He was initially started on cytarabine, doxorubicin and all-trans retinoic acid (ATRA) but he developed dyspnea which was thought to be secondary to differentiation syndrome. He was started on dexamethasone 10 mg BID. This was tapered to 4 mg daily over several days. He had a prolonged hospitalization due to neutropenic fever. Two weeks after initiation of chemotherapy the patient complained of chest pain and worsening dyspnea. EKG performed showed ST elevations in leads II, III and aVF with premature atrial complexes (Fig. 1).

The patient was given nitroglycerine and intravenous metoprolol tartrate. He was taken to cardiac catheterization laboratory for a suspected myocardial infarction. In the laboratory, his EKG changes reversed and his symptom of chest pain resolved. Coronary arteriogram showed patent coronary arteries. Echocardiogram showed a normal ejection fraction without any regional wall motion abnormalities or pericardial effusion. He became hypotensive post procedure (possibly secondary to nitroglycerine and beta-blocker) and was started on dopamine infusion and transferred to the ICU.

He complained of ongoing dyspnea but had no other complaints. His blood pressure was 100/56, pulse 71/min and regular and pulse oximetry of 99% on 3 liters oxygen via nasal cannula. Pulmonary examination showed a few rhonchi and crackles at the right base. Rest of his physical examination was normal. Laboratory data showed a hemoglobin of 6.6 g/dL, WBC count 400/UL with absolute neutrophil count of 300/μL, platelets 37,000/μL, BUN 30 mg/dL, creatinine 1.5 mg/dL, troponin I 0.28 ng/mL and CPK 91 U/L. Chest x-ray showed pulmonary vascular prominence com-
compatible with fluid overload versus differentiation syndrome. A ventilation perfusion lung scan showed low probability for a pulmonary embolism.

He was receiving ceftazidime for neutropenic fever. Dexamethasone was increased to 10 mg BID for the differentiation syndrome. He received transfusion of one unit of packed red blood cells. He was weaned off the dopamine the next day and was transferred to telemetry. His hospital course was complicated by pancytopenia requiring multiple transfusions of packed red blood cells and platelets. Ceftazidime was discontinued once his fevers subsided, and his cultures came back negative. He was restarted on amoxicillin for prophylaxis against his previous group-B streptococcal sepsis. Initially, he did not receive diuretics due to hypotension. Once his blood pressure stabilized, he was diuresed. His dyspnea improved with combination of diuresis, steroids and packed red blood cell transfusion. He was discharged home with a slowly tapering dose of dexamethasone.

**Discussion**

Cardiotoxicity is a not uncommon side effect of chemotherapy. Coronary vasospasm mimicking myocardial infarction has been described in patients receiving 5-fluorouracil and capecitabine, a pro-drug of 5-fluorouracil [7]. Hemorrhagic myocarditis caused by high-dose cyclophosphamide, potentiation of the cardiotoxic effect of anthracyclines by dacarbazine and plicamycin and serious ventricular and supraventricular arrhythmias induced by amsacrine have been reported [8-10]. Ischemic VT and polymorphic PVCs associated with a prolongation of QT interval secondary to 5-fluorouracil-induced vasospasm have been reported [11, 12].

ATRA has revolutionized the treatment of APL. Addition of ATRA to anthracyclines has been shown to improve disease-free survival and overall survival [13]. Although, ATRA is considered a safe medication with mild adverse reactions, retinoic acid syndrome (RAS) or differentiation syndrome is a serious and potentially fatal side effect seen in up to 2-25% of patients undergoing induction chemotherapy [14]. The onset of the syndrome ranges from 2 to 21 days (median period of 10 days) after initiating ATRA therapy.

The characteristic features of RAS include unexplained fever, pulmonary infiltrates and effusions associated respiratory distress, weight gain, elevated white blood cells, pericardial effusion, episodic hypotension and acute renal failure. The reported mortality from RAS is up to 2% [15-17]. At least three of the following signs and/or symptoms should be present to diagnose RAS: fever, weight gain, pulmonary infiltrates, pleural or pericardial effusions, respiratory distress, hypotension and renal failure. The exact pathogenesis of RAS is unclear. It is theorized that ATRA-treated APL cells release inflammatory cytokines including interleukin IL-1b, IL-6, IL-8 and tumor necrosis factor alpha (TNF-α). This release of cytokines can lead to endothelial damage. Tissue infiltration of APL cells may contribute to the syndrome [18].

Cardiac manifestations reported with ATRA-induced differentiation syndrome include pericardial effusion (19%), cardiac tamponade with cardiogenic shock [19], and myocarditis [20-24]. Reversible myocardial stunning has been described in a patient with non-obstructive coronary artery disease [25]. One patient receiving ATRA developed an acute myocardial infarction and lacunar cerebral infarction [26]. The exact pathogenesis of these events is unknown. One possibility is ATRA-induced coronary vasospasm resulting in myocardial infarction and myocardial stunning. Thromboembolism is a well-recognized complication associated with APL [27-29]. ATRA can increase the pro-coagulant state of APL, and the risk of thromboembolism rises to 5% [30, 31]. The release of inflammatory cytokines seen with RAS leads to endothelial injury and dysfunction, which may increase this risk.

ATRA has revolutionized the treatment of APL. In most patients, only mild adverse effects are noted. However, RAS is a potentially fatal complication. ATRA has been reported to cause pericardial effusion with cardiac tamponade, myocarditis, myocardial stunning and myocardial infarction. We report a case of ATRA-induced differentiation syndrome resulting in clinical presentation of inferior STEMI based on EKG and troponin I results. Coronary arteriography showed non-obstructive coronary artery disease. EKG changes were transient and reversed by nitrates. Coronary vasospasm, possibly induced by ATRA is the likely mechanism.

Figure 1. EKG performed showed ST elevations in leads II, III and aVF with premature atrial complexes.
Disclosure

Authors have not received any funding or grants to support this project.

References


